

**AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—ACC 2015 COCATS 4 INTRODUCTION**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speakers Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional/ Organizational or Other Financial Benefit</b>	<b>Expert Witness</b>
Valentin Fuster	Icahn School of Medicine at Mount Sinai, Zena and Michael A. Wiener Cardiovascular Institute—Director	None	None	None	<ul style="list-style-type: none"> <li>• AstraZeneca†</li> </ul>	<ul style="list-style-type: none"> <li>• National Heart, Lung, and Blood Institute†</li> <li>• American Heart Association†</li> </ul>	None
Jonathan L. Halperin	Icahn School of Medicine at Mount Sinai—Professor of Medicine	<ul style="list-style-type: none"> <li>• AstraZeneca</li> <li>• Bayer</li> <li>• Biotronic*</li> <li>• Bristol-Myers Squibb</li> <li>• Boehringer Ingelheim*</li> <li>• Boston Scientific</li> <li>• Daiichi-Sankyo</li> <li>• Johnson &amp; Johnson</li> <li>• Medtronic</li> <li>• Ortho-Mcneil-Janssen Pharmaceuticals</li> <li>• Pfizer</li> <li>• Sanofi-aventis*</li> </ul>	None	None	None	<ul style="list-style-type: none"> <li>• National Heart, Lung, and Blood Institute†</li> <li>• National Institutes of Health†</li> </ul>	<ul style="list-style-type: none"> <li>• Plaintiff, coronary artery disease, 2015</li> <li>• Plaintiff, coronary artery disease, 2013†</li> </ul>
Eric S. Williams	Indiana University School of Medicine—Professor (Cardiology) and Associate Dean; Indiana University Health—Cardiology Service Line Leader	None	None	None	None	None	<ul style="list-style-type: none"> <li>• Third party, case review, 2012†</li> </ul>

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

\*Significant relationship.

†No financial benefit.